Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry

Eliglustat is a recently approved oral therapy in the United States and Europe for adults with Gaucher disease type 1 who are CYP2D6 extensive, intermediate, or poor metabolizers (> 90% of patients) that has been shown to decrease spleen and liver volume and increase hemoglobin concentrations and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Jennifer, Underhill, Lisa H., Taylor, John S., Angell, Jennifer, Peterschmitt, M. Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927653/
https://www.ncbi.nlm.nih.gov/pubmed/27408819
http://dx.doi.org/10.1016/j.ymgmr.2016.06.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927653/
https://www.ncbi.nlm.nih.gov/pubmed/27408819
http://dx.doi.org/10.1016/j.ymgmr.2016.06.003

Ejemplares similares